JAKARTA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Wintermar’s Operating Profit jumped 55.8%YOY to US$8.9million for 1H2025, derived from 17% growth in Owned Vessel Revenue in 1H2025 and higher gross margins from better fleet mix and higher charter rates.Owned Vessel revenues were higher in 1H2025 compared to 1H2024 despite lower utilization due to better yielding vessels in operation in 1H2025. Owned Vessel DivisionAlthough the number of vessels has not changed, fleet composition has improved with 2 additional PSVs in operation in 1H2025 as well as 3 newly delivered HLBs which 2 units commenced work in April 2025 and 1 unit in July 2025. With 4 additional units of higher yielding vessels in operation compared to last year, gross margins from the Owned Vessels Division expanded from 29.6% in 1H2024 to 39.1% in 1H2025. This resulted in a 54.4%YOY jump in Gross Profit growth for the Owned Vessel Division to US$12.4million, despite a fall in utilization from 63.7% in FY2024 to 57.9% in 1H2025.Despite a slower first half of the year which caused a dip in utilization, the Company reaped the benefit of improving average charter rates from a higher number of operational vessels a...

Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum-resistant security validations across both Web3 and traditional Web2 infrastructures. Embedded at the Sub-Zero layer within a Decentralized Trust Mesh, $NAORIS powers autonomo...

HAYWARD, CALIFORNIA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog's acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.Today, Biolog's TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology - supporting clinic...

ANKARA, Turkey, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetrati...

HONG KONG, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company's leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification...

香港，2025年7月28日 - (亚太商讯 via SeaPRwire.com) - 小黄鸭德盈控股国际有限公司（及其下属公司合称为「小黄鸭德盈」或「集团」，股份代号：2250）公布截至2025年6月30日止六个月（「期内」或「上半年」）盈利预告。期内，受益于集团角色授权业务的授权金收入显著增长、设计咨询服务费增加，以及电子商务及其他业务收入因持续于电商平台开展推广工作而扩展等，预期集团整体业绩改善。就集团上半年未经审核综合管理账目所作的初步评估（不包括合约资产、金融资产减值及公允值变动），预期小黄鸭德盈期内收入较上年的5,992万港元同比大幅增长不低于30%。同时，经营亏损亦较上年大幅收窄不少于30%。小黄鸭德盈近年持续以创新驱动IP生态发展及系统协同，透过「IP+全产业链」的前瞻性布局，推动集团业务发展和全球化布局加速。未来，小黄鸭德盈将继续创新商业模式，强化IP生态系统的协同效应，致力实现品牌价值与商业价值的长期稳健发展与共赢成长。关于小黄鸭德盈控股国际有限公司小黄鸭德盈控股国际有限公司是一家主要从事角色知识产权业务的投资控股公司。集团自 2005 年创立明星 IP「B.Duck 小黄鸭」以来，在 IP 各类授权及运营上拥有丰富经验。集团着力于 IP 实景文旅、游戏文娱、商品零售、跨境出海等业务增长点，实现IP授权、商品企划、供应链、销售渠道等业务板块的优化整合，小黄鸭德盈不断深化 IP 商业化生态圈建设，致力打造 B.Duck 成为「全球快乐符号」，推动「Make A Playful World」的使命落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年7月28日 - (亚太商讯 via SeaPRwire.com) - 日本东京证券交易所挂牌企业 Quantum Solutions Co., Ltd. （东京证券交易所上市编号：2338）及其关联公司（「Quantum Solutions集团」或「Quantum Solutions」）今日进一步公布集团在数字资产领域的战略部署，并与亚洲知名数字资产科技公司 TDX Strategies Ltd 签署业务合作协议。双方将于比特币交易执行、资产托管、结构化产品设计以及市场风险管理等方面展开全面合作，为 Quantum Solutions 的比特币储备计划提供一站式技术与服务支持。Quantum Solutions 早前已公布，将于未来12个月内逐步建仓最多3,000枚比特币，以对冲通胀风险、优化资产结构并提升财务系统的灵活性。本次与 TDX Strategies 的合作，标志着相关业务从资本层面正式迈入系统化执行阶段，合作框架的落地有望全面强化Quantum Solutions于数字资产运作方面的专业能力与风控保障。TDX Strategies 是一家专门从事数字结构化产品交易服务的科技型企业，在英属处女群岛（BVI）合法持有投资交易与营运许可。该公司拥有丰富的区块链资产操作经验与跨市场机构资源网络，并与多家亚洲家族办公室、资产管理机构及企业建立了长期合作。根据本次合作，Quantum Solutions 同意于未来24个月内非独家形式优先考虑订阅TDX 提供的加密货币服务、，以保障储备业务的灵活性与稳定性。根据协议，TDX Strategies 将为 Quantum Solutions 的比特币业务提供多层次支持，包括：协助构建比特币交易与执行机制，以实现不同市场条件下的最优采购策略；建立符合企业级标准的冷／热钱包管理系统与多重签名安全架构，保障数字资产的托管与操作安全；根据持仓比特币设计具备本金保障与收益增值潜力的结构化产品，提升资产使用效率；同时亦将于营运、技术、风险敞口控管、市场波动应对等领域提供持续的技术咨询与策略建议。TDX Strategies 为一间科创型数字资产公司，在结构化金融工具、机构化交易系统、跨链资产解决方案方面具备实操经验，技术团队专长横跨区块链应用与传统风控体系，于亚洲加密金融圈建立稳固声誉。值得一提的是，TDX 属 Quantum Solutions 的战略合作方，美国著名财经媒体 福布斯Forbes Media LLC幕后东主任德章先生集团旗下。任德章先生同时亦为 Integrated Asset Management (Asia) Limited 的全资拥有人。该机构早前已向 Quantum Solutions 集团 提供 1,000 万美元贷款，用以启动比特币储备计划的首阶段资金投入。作为国际知名投资人，任...

土耳其安卡拉, 2025年7月29日 - (亚太商讯 via SeaPRwire.com) - GEN制药公司（GENIL.IS）是土耳其领先的专业制药公司，日前宣布其第一阶段临床试验取得积极结果。该试验旨在评估首创且新型的口服线粒体靶向候选药物 SUL-238 在健康老年志愿者中的安全性、耐受性以及药代动力学（PK）表现。研究结果已在2025年阿尔茨海默病协会国际会议（AAIC®）上于多伦多公布。本次第一阶段临床试验为首个人体试验，采用单次口服递增剂量（SAD）设计，随机、双盲、安慰剂对照，共分为三个部分，纳入了共计53名健康老年志愿者。第一部分包括6个剂量组（口服剂量分别为50、100、250、500、1000和2000毫克，n=23）。第二部分中，研究了单剂1000毫克口服剂量在10名健康老年人的药代动力学特征。第二部分B评估了食物的影响，采用随机、单剂2000毫克口服、双处理、双周期交叉设计（n=20）。试验结果显示，50至2000毫克的单次口服剂量 SUL-238 在受试者中均表现出良好的安全性和耐受性，同时具备良好的药代动力学特征，并能较好地渗透至脑脊液（CSF）。这些结果使得 SUL-238 成为治疗包括阿尔茨海默病在内的神经退行性疾病的有前景的临床开发候选药物。未观察到任何不良反应（AEs）限制剂量递增，SUL-238组与安慰剂组的不良事件发生率相当，且所有不良事件均为轻度或中度。平均终末消除半衰期为0.86至3.80小时，达峰时间为0.50至1.39小时。在进食状态下，血浆药物最大浓度（Cmax）和血浆浓度-时间曲线下面积(AUC0-∞) 分别下降了50%和60%。给药后2小时和8小时脑脊液与血浆的浓度比例分别为21.1%（±6.6%）和74.2%（±46.0%）。GEN董事长 Abidin Gülmüş 表示：“这些令人鼓舞的首次人体试验结果为我们带来了极大信心，标志着我们在应对阿尔茨海默病潜在生物机制方面迈出了重要一步。”GEN研发副总裁、医学博士兼博士 Nadir Ulu 补充道：“在本次第一阶段试验中，SUL-238 展现出优异的安全性和药代动力学特征，结合扎实的临床前数据，使其成为未来临床开发的有力候选药物，有望满足包括阿尔茨海默病在内的神经退行性疾病领域亟待解决的临床需求。”关于 SUL-238SUL-238 是一种首创的新型小分子药物，其源自冬眠机制，靶向细胞的“能量工厂”——线粒体。该药物通过激活线粒体复合体 I 和 IV 来支持线粒体的生物能量代谢，并已在神经退行性疾病、心血管疾病、肾脏疾病及衰老的啮齿动物模型中显著改善线粒体功能。SUL-238 能穿越血脑屏障，并已在临床前研究和第一阶段试验中完成了广泛的安全性评估。GEN 获得了 Sulfateq BV 授权，可将 SUL-238 应用于神经退行性疾病的治疗开发。关于 ...

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by th...